Biocardia stock.
The estimated Net Worth of Peter Altman is at least $883 Thousand dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $205,985 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer, and Director at BioCardia.
Nov 16, 2023 · SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular ... Stock split history for BioCardia since 2019. Prices shown are actual historical values and are not adjusted for either splits or dividends.Nov 14, 2023 · BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 14d Why Beyond Air Shares Are Trading Lower By Around 37%? BioCardia Inc (NASDAQ: BCDA) said the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase 3 pivotal CardiAMP Cell
BioCardia Inc (BCDA) stock is trading at $2.16 as of 10:19 AM on Friday, Jun 9, an increase of $0.04, or 1.89% from the previous closing price of $2.12. The stock has traded between $2.15 and $2.18 so far today. Volume today is light. So far 5,707 shares have traded compared to average volume of 41,498 shares.Mr. McClung BCDA stock SEC Form 4 insiders trading. David has made over 5 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 1,600 units of BCDA stock worth $4,096 on 5 November 2018.1,600 units of BCDA stock worth $4,096 on 5 November 2018.The estimated Net Worth of Peter Altman is at least $849 Tausend dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $171,654 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer und Director at BioCardia.
Nov 18, 2023 · BioCardia Stock Down 10.0 %. NASDAQ BCDA opened at $0.72 on Tuesday. The stock has a market capitalization of $15.59 million, a P/E ratio of -1.16 and a beta of 1.29. BioCardia has a 52-week low of $0.36 and a 52-week high of $2.92. The firm has a 50-day moving average price of $0.44 and a 200 day moving average price of $1.26.
May 30, 2023 · BioCardia has made significant progress in the development of its therapeutic candidates BCDA-01 and BCDA-02. Check out my recommendation on BCDA stock. Stock Performance. Shares of BioCardia were trading at $0.405 as of November 06. Over the last 52-week period, shares are down 78.11%. Given that these returns are generally negative, long-term ...BioCardia (Nasdaq:BCDA) - Stock Price, News & Analysis - Simply Wall St Stocks / United States / Pharmaceuticals & Biotech BioCardia NasdaqCM:BCDA …Discover historical prices for ME stock on Yahoo Finance. View daily, weekly or monthly format back to when 23andMe Holding Co. stock was issued.
Mohammed Haneefa Nizamudeen. I first wrote about BioCardia (NASDAQ:BCDA) in June of 2021, explaining why I'd taken a speculative-sized position in the stock.Since then the share price is down (as ...
Nov 16, 2023 · BioCardia, Inc. announced a definitive agreement with a healthcare-focused institutional investor for the purchase and sale of 2,000,000 shares of the Company’s common stock at a purchase price of $0.65 per share in a registered direct offering.
BioCardia Inc (BCDA) stock is trading at $0.88 as of 9:36 AM on Thursday, Nov 16, a loss of -$0.07, or -6.91% from the previous closing price of $0.95. The stock has traded between $0.84 and $0.89 so far today. Volume today is light. So far 173,359 shares have traded compared to average volume of 4,872,239 shares.Understanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.BioCardia, Inc. Common Stock (BCDA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Stock analysis for BioCardia Inc (BCDA:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Are you tired of spending endless hours searching for high-quality stock photos only to discover that they come with a hefty price tag? Look no further. In this article, we will explore the best sources for high-quality really free stock ph...
Nov 17, 2023 · Source. Headline. Genocea Biosciences (NASDAQ:GNCAQ) vs. BioCardia (NASDAQ:BCDA) Financial Analysis. americanbankingnews.com - November 17 at 1:30 AM. BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. finance.yahoo.com - November 16 at 3:00 PM. 2023 BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval 16 Nov 2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules BioCardia has received a go-ahead from the FDA for a first-in-human trial of a second version of its stem cell implants designed to help rescue patients from heart failure. The green light clears ...SAN CARLOS, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- BioCardia®, Inc. (Nasdaq: BCDA)(BioCardia or the “Company”) today announced it has entered into definitive agreements with investors for ...Nov 14, 2023 · The FDA approved BioCardia Inc's (NASDAQ: BCDA) Phase 3 CardiAMP Heart Failure II study protocol of CardiAMP autologous cell therapy for ischemic heart failure. The currently ongoing CardiAMP ...
Stock split history for BioCardia since 2019. Prices shown are actual historical values and are not adjusted for either splits or dividends.
Nov 16, 2023 · BioCardia, Inc. announced a definitive agreement with a healthcare-focused institutional investor for the purchase and sale of 2,000,000 shares of the Company’s common stock at a purchase price of $0.65 per share in a registered direct offering. BioCardia, Inc. (BCDA) delivered earnings and revenue surprises of -30.77% and 81.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?Get the latest BioCardia (BCDAW) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. ... Stock Market ...$1.0401 0.6411 [160.68%] Last update: 4:12PM (Delayed 15-Minutes) Get Real Time Here $1.0401 0 [0.00%] Profile News Analyst Ratings Guidance Dividends …2023 BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules. 14 Nov 2023 BioCardia Announces FDA Approval of CardiAMP Heart Failure II Protocol for Autologous Cell Therapy for Ischemic Heart Failure. 08 NovDavid has made over 5 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he bought 1,600 units of BCDA stock worth $4,096 on 5 November 2018.Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods that may have been lost or stolen.What is the target price for BioCardia (BCDA) stock? The latest price target for BioCardia ( NASDAQ: BCDA) was reported by HC Wainwright & Co. on Wednesday, October 11, 2023. The analyst firm set ...
BioCardia : FORM OF SECURITIES PURCHASE AGREEMENT - Form 8-K Nov. 16: PU BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules Nov. 16: AQ
BioCardia BCDA is set to give its latest quarterly earnings report on Wednesday, 2023-11-08. ... Stock Performance. Shares of BioCardia were trading at $0.405 as of November 06.
5 Sep 2023 ... Biocardia stock dropped from about $2 on July 21 to $1.10 on July 24, when the concerns of the DSMB were first revealed. After drifting down ...Find real-time BCDA - BioCardia Inc stock quotes, company profile, news and forecasts from CNN Business. The estimated Net Worth of Richard M Krasno is at least $297 Thousand dollars as of 17 June 2019. Mr. Krasno owns over 20,000 units of BioCardia stock worth over $27,300 and over the last 17 years he sold BCDA stock worth over $0. In addition, he makes $269,814 as Independent Director at BioCardia.BioCardia Stock Price, News & Analysis (NASDAQ:BCDA) $0.63 -0.05 (-7.35%) (As of 12:50 PM ET) Compare Today's Range $0.62 $0.69 50-Day Range $0.37 …The main U.S. stock indexes were poised for strong opening gains on Tuesday after cooler-than-expected inflation data boosted expectations that the Federal Reserve was done raising interest rates.At 9:12 ET, Dow e-minis (1YMc1) were up 1.03% at 34,738. ... ** BioCardia BCDA: up 263.4% premarket. BUZZ - Rises on FDA's nod to …Real stock prices are not the same as the last traded stock price. Real stock prices are adjustments to closing stock prices. The adjustments are used in a variety of ways, including dividends, the range of prices and the closing price of t...Find the latest BioCardia, Inc. (BCDA) stock quote, history, news and other vital information to help you with your stock trading and investing. 16 Nov 2023 ... BioCardia develops cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. Stock BCDA logo. BioCardia ...BioCardia Inc (NASDAQ: BCDA) said the independent Data Safety Monitoring Board (DSMB) has completed its prespecified data review for the ongoing Phase 3 pivotal CardiAMP Cell
Mr. Fernandez BCDA stock SEC Form 4 insiders trading. Fernando has made over 1 trades of the BioCardia stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 14,277 units of BCDA stock worth $28,554 on 13 January 2018.14,277 units of BCDA stock worth $28,554 on 13 January 2018.The estimated Net Worth of Simon H Stertzer is at least $461 Thousand dollars as of 5 July 2019. Simon Stertzer owns over 166,666 units of BioCardia stock worth over $385,217 and over the last 7 years he sold BCDA stock worth over $0. In addition, he makes $76,250 as Independent Chairman of the Board at BioCardia.BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules GlobeNewswire 17d Why Beyond Air Shares Are Trading Lower By Around 37%?Instagram:https://instagram. otcmkts sqzbbest micro cap stocksgrace kennedybodylase med spa reviews Stock screener. Filter, compare, and track stocks. Insiders trading. See how executives trade. Heat map. Visualize ratios & metrics. Histogram. See ratios across industries. ... As the Vice President - Operations of BioCardia, the total compensation of Phil Pesta at BioCardia is $276,000. stock option service3d printers under dollar200 View the latest BioCardia Inc. (BCDA) stock price, news, historical charts, analyst ratings and financial information from WSJ. The estimated Net Worth of Richard M Krasno is at least $385 Thousand dollars as of 17 June 2019. Mr. Krasno owns over 20,000 units of BioCardia stock worth over $114,800 and over the last 17 years he sold BCDA stock worth over $0. In addition, he makes $269,814 as Independent Director at BioCardia. best rated wealth management firms BioCardia (NASDAQ:BCDA) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap medical companies, but which is the better investment?We will compare the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, dividends, community ranking, profitability, media sentiment, risk and valuation.If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...The estimated Net Worth of Peter Altman is at least $913 Thousand dollars as of 28 June 2019. Peter Altman owns over 600 units of BioCardia stock worth over $235,166 and over the last 5 years he sold BCDA stock worth over $0. In addition, he makes $677,501 as President, Chief Executive Officer, and Director at BioCardia.